Nabumetone
- Atc Codes:M01AX01
- CAS Codes:42924-53-8
- PHARMGKB ID:42924-53-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Gambaran; Czech Republic: Relifex; Denmark: Nabumeton, Relifex; Estonia: Nabumetone, Relifex; Finland: Nabumeton, Relifex; France: Nabucox; Germany: Arthaxan, Relifex; Greece: Relifex; Hungary: Relifex; Ireland: Relifex, Religer; Italy: Artaxan, Nabuser, Relifex; Latvia: Nabumetone, Relifex; Lithuania: Nabumetone, Relifex; Netherlands: Mebutan, Nabumeton; Poland: Coxalgan, Coxeton, Nabumeton, Nabuton, Quolifex, Recox, Relibuton, Relifex, Rodanol S, Stavin; Portugal: Balmox, Elitar, Nabumetona; Slovenia: Rodanol; Spain: Relif; Sweden: Nabumeton, Relifex; UK: Nabumetone, Relifex.
North America
Canada: Nabumetone; USA: Nabumetone.
Latin America
Mexico: Naflam, Relifex.
Asia
Japan: Relafen.
Drug combinations
Chemistry
Nabumetone: C~15~H~16~O~2~. Mw: 228.29. (1) 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-; (2) 4-(6-Methoxy-2-naphthyl)-2-butanone. CAS-42924-53-8 (1986).
Pharmacologic Category
Analgesics and Antipyretics; Other Nonsteroidal Anti-inflammatory Agents. (ATC-Code: M01AX01).
Mechanism of action
Prodrug with little pharmacologic activity until oxidized in liver to form active metabolite structurally similar to naproxen. Active metabolite of nabumetone inhibits cyclooxygenase-1 and 2 (COX-1/PTGS1 and COX-2/PTGS2) enzymes, which results in decreased formation of prostaglandin precursors. Has antipyretic, analgesic, and anti-inflammatory properties.
Therapeutic use
Symptomatic treatment of osteoarthritis and rheumatoid arthritis.
Pregnancy and lactiation implications
Avoid use in 3^rd^ trimester due to possible premature closure of ductus arteriosus. Not recommended in nursing women.
Unlabeled use
Moderate pain.
Contraindications
Hypersensitivity to nabumetone, aspirin, other NSAIDs, or any component of the formulation. History of asthma, urticaria, or other sensitivity reaction precipitated by aspirin or other NSAIDs. Treatment of perioperative pain in setting of coronary artery bypass graft surgery.
Warnings and precautions
NSAIDs associated with increased risk of adverse cardiovascular events, including myocardial infarction, stroke, and new onset or worsening of pre-existing hypertension; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease (use caution with fluid retention, heart failure, or hypertension). Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with cardioprotective effect of aspirin. Use contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery. Dizziness common, may cause nervousness, may rarely cause insomnia, confusion, depression, somnolence or hallucinations. May cause photosensitivity reactions, exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis (do not use in patients who experience urticaria with NSAID or aspirin therapy). NSAIDs may increase risk of GI irritation, inflammation, ulceration, bleeding, and perforation (use caution with history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). Use with caution in decreased hepatic function (rarely, severe hepatic reactions (e.g. fulminant hepatitis, liver failure) occurred with NSAID use). May compromise existing renal function; patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACEIs, and the elderly are at greater risk of renal toxicity. Not recommended for use in advanced renal disease. Long-term NSAID use may result in renal papillary necrosis. Platelet adhesion and aggregation may be decreased; may prolong bleeding time. Anemia may occur. Do not administer in aspirin-sensitive asthma, bronchospasm, rhinitis. Use caution in other forms of asthma.